PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

被引：0
|
作者：
Xiangyu Qiu
Zhaoan Yu
Xiaoqing Lu
Xin Jin
Jinrong Zhu
Rongxin Zhang
机构：
[1] GuangdongProvincialKeyLaboratoryofAdvancedDrugDelivery,GuangdongProvincialEngineeringCenterofTopicalPreciseDrugDeliverySystem,SchoolofLifeSciencesandBiopharmaceutics,GuangdongPharmaceuticalUniversity
来源：
Cancer Biology & Medicine | 2024年 / 21卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R730.5 [肿瘤治疗学];
学科分类号：
摘要：
<正>The emergence of tumor immunotherapy represents a pivotal milestone in cancer treatment, heralding new hope for cancer patients globally. Immune checkpoint inhibitors have been instrumental in this advance, playing a crucial role in modulating the immune system response to neoplasms. Specifically, the therapies targeting the programmed death 1/programmed cell death ligand 1（PD-1/PD-L1） immune checkpoint pathways have shown significant efficacy in treating various cancers1.
引用
收藏
页码：970 / 976
页数：7
相关论文
共 50 条
  • [21] The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors
    Goldberg, Monica V.
    Woo, Seng-Ryong
    Bankoti, Jaishree
    Selby, Mark
    Nirschi, Christopher J.
    Bettini, Matthew L.
    Vogel, Peter
    Grosso, Joseph F.
    Netto, George
    Chaux, Alcides
    Smeltzer, Matthew
    Workman, Creg J.
    Pardoll, Drew M.
    Korman, Alan J.
    Vignali, Dario A. A.
    Drake, Charles G.
    CANCER RESEARCH, 2011, 71
  • [22] Humanized PD-1/LAG-3 mice for preclinical evaluation of combination therapy
    Duan, Feifei
    Yang, Xiaoliu
    Ju, Cunxiang
    Zhao, Jing
    Gao, Xiang
    Chen, Santi Suryani
    CANCER RESEARCH, 2022, 82 (12)
  • [23] The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
    Kreidieh, Firas Y.
    Tawbi, Hussein A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [24] The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
    Kreidieh, Firas Y.
    Tawbi, Hussein A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [25] CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
    Chocarro, L. D. E.
    Blanco, E.
    Fenandez-Rubio, L.
    Garnica, M.
    Zuazo, M.
    Garcia Granda, M. J.
    Bocanegra, A.
    Echaide, M.
    Johnston, C.
    Edwards, C. J.
    Legg, J.
    Pierce, A.
    Arasanz, H.
    Fernandez-Hinojal, G.
    Vera, R.
    Ausin, K.
    Santamaria, E.
    Fernandez-Irigoyen, J.
    Kochan, G.
    Escors, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S216 - S216
  • [26] Clinical blockade of PD1 and LAG3-potential mechanisms of action
    Nguyen, Linh T.
    Ohashi, Pamela S.
    NATURE REVIEWS IMMUNOLOGY, 2015, 15 (01) : 45 - 56
  • [27] Clinical blockade of PD1 and LAG3 — potential mechanisms of action
    Linh T. Nguyen
    Pamela S. Ohashi
    Nature Reviews Immunology, 2015, 15 : 45 - 56
  • [28] Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
    Saleh, Reem
    Toor, Salman M.
    Khalaf, Sarah
    Elkord, Eyad
    VACCINES, 2019, 7 (04)
  • [29] TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
    Ghosh, Srimoyee
    Sharma, Geeta
    Travers, Jon
    Kumar, Sujatha
    Choi, Justin
    Jun, H. Toni
    Kehry, Marilyn
    Ramaswamy, Sridhar
    Jenkins, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 632 - 641
  • [30] Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth.
    Huang, Ruea-Yea
    McGray, A. J.
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2016, 22
12345